Do you want to read an article? Please log in or register.
Comparative effects of sulfonylureas, DPP4is and SGLT2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care
Glycemic Control
Related content
COMMENTED
Type 2 Diabetes
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M, CVD-REAL 2 Investigators and Study Group
doi: 10.1016/S2213-8587(20)30130-3.
Type 2 Diabetes
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
JAMA Intern Med
Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Al-Aly Z
doi: 10.1001/jamainternmed.2021.2488
COMMENTED
Type 2 Diabetes
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, Wilding JPH, Garcia Rodriguez LA, Cea-Soriano L, Kohsaka S, Nicolucci A, Lucisano G, Lin FJ, Wang CY, Wittbrodt E, Fenici P, Kosiborod M
doi: 10.1016/S2213-8587(19)30384-5.
RECOMMENDED
Type 2 Diabetes
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
Circulation.
Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S
doi: 10.1161/CIRCULATIONAHA.118.039177.
COMMENTED
Diabetes - GeneralType 2 Diabetes
Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
BMJ
Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S
doi: 10.1136/bmj.k2693.
COMMENTED
Diabetes - General
Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Cardiovasc Diabetol
Lohia P, Kapur S, Benjaram S, Cantor Z, Mahabadi N, Mir T, Badr MS
doi: 10.1186/s12933-021-01336-0
Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalisation and mortality records.
Diabetes Obes Metab.
Zghebi SS, Steinke DT, Rutter MK, Emsley RA, Ashcroft DM
doi: 10.1111/dom.12692.
COMMENTED
Glycemic Control
Glycemic Control and Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort Study
Diabetes Care.
Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG
doi: 10.2337/dc18-0287.
COMMENTED
Diabetic Complications
Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease: A Propensity Score-Matched Analysis of a Nationwide, Biopsy-Based Cohort Study
Diabetes Care.
Yamanouchi M, Furuichi K, Hoshino J, Toyama T, Hara A, Shimizu M, Kinowaki K, Fujii T, Ohashi K, Yuzawa Y, Kitamura H, Suzuki Y, Sato H, Uesugi N, Hisano S, Ueda Y, Nishi S, Yokoyama H, Nishino T, Samejima K, Kohagura K, Shibagaki Y, Mise K, Makino H, Matsuo S, Ubara Y, Wada T, Research Group of Diabetic Nephropathy, the Ministry of Health, Labour and Welfare, and the Japan Agency for Medical Research and Development
doi: 10.2337/dc18-1320.